Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harrow Inc HROW

Healthcare Biotechnology
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America... see more

Recent & Breaking News (NDAQ:HROW)

Melt Pharmaceuticals' MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study

Business Wire December 21, 2022

Harrow Secures Capital to Close Recently Announced Acquisition

Business Wire December 16, 2022

Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and "BB" Rating from Egan-Jones

Business Wire December 14, 2022

Harrow Prices $25 Million Offering

Business Wire December 14, 2022

Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®

Business Wire December 14, 2022

Harrow and iOR Partners Expand National Product Supply Agreement

Business Wire November 30, 2022

Harrow Announces Third Quarter 2022 Financial Results

Business Wire November 14, 2022

Harrow Launches Atropine.com

Business Wire November 10, 2022

Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022

Business Wire October 28, 2022

Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300

Business Wire October 27, 2022

Harrow Sells Non-Ophthalmic Compounding Business

Business Wire October 5, 2022

ImprimisRx Launches Fortisite(TM) (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation

Business Wire September 29, 2022

Harrow Announces U.S. FDA Approval of IHEEZO(TM) (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

Business Wire September 27, 2022

Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Business Wire August 11, 2022

Harrow Health Announces Second Quarter 2022 Financial Results

Business Wire August 9, 2022

Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022

Business Wire July 27, 2022

Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States

Business Wire June 24, 2022

Harrow Health Announces First Quarter 2022 Financial Results

Business Wire May 5, 2022

Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation

Business Wire May 4, 2022

Harrow Health to Participate in B. Riley Securities' Annual Neuro & Ophthalmology Investor Conference

Business Wire April 22, 2022